Abionyx Pharma SA (ABNX)

Paris

Currency in EUR

2.1000

+0.1880(+9.83%)

Real-time Data·12:34:54

Fair Value

Unlock Value

Day's Range

1.9100

2.1950

52 wk Range

1.0860

2.1950

ABNX Financial Summary

A brief financial summary of Abionyx Pharma SA as well as the most significant critical numbers from each of its financial reports. In addition, some financial ratios derived from these reports are featured. Users can opt to see 4 periods of either annual or quarterly information.

Key Ratios

P/E Ratio-9.38

Price/Book5.63

Debt / Equity36.69%

Return on Equity-56.76%

Dividend Yield0.00%

EBITDA-4.34M

Fair ValueUnlock

Fair Value UpsideUnlock

Statements Highlights

Period Ending:

2015

31/12

2016

31/12

2017

31/12

2018

31/12

2019

31/12

2020

31/12

2021

31/12

2022

31/12

2023

31/12

2024

31/12

Income Statement

Total Revenues

aa.aa

0.68

5.25

4.64

4.55

Gross Profit

aa.aa

0.26

0.64

0.62

0.84

Operating Income

aa.aa

-2.97

-5.95

-4.11

-3.41

-4.47

Net Income

aa.aa

-1.89

-5.82

-4.21

-3.52

-4.38

Balance Sheet

Total Assets

aa.aa

10.29

21.83

15.82

14.83

13.54

Total Current Liabilities

aa.aa

3.6

6.75

5.09

3.93

3.71

Total Equity

aa.aa

6.63

10.68

7.17

7.92

7.52

Cash Flow

Levered Free Cash Flow

aa.aa

0.3

-5.04

-2.06

-2.47

-1.85

Cash from Operations

aa.aa

-0.6

-6.69

-3.36

-3.7

-3.63

Cash from Investing

aa.aa

-0.13

1.34

-0.18

-0.13

-0.08

Cash from Financing

aa.aa

1.55

3.97

-0.19

3.89

2.84

Net Change in Cash

aa.aa

0.82

-1.38

-3.73

0.06

-0.87

* In Millions of EUR (except for per share items)

Analyst Ratings

2 Buy

0 Hold

0 Sell

Ratings:

2 analysts

Overall Consensus

Strong Buy

Analysts 12-Month Price Target:

Average 10.7500

(+411.90% Upside)

Earnings

Latest Release

May 28, 2025

EPS / Forecast

-- / --

Revenue / Forecast

1.00M / --

EPS Revisions

Unlock

Last 90 days

FAQ

What was Abionyx Pharma SA's net income for the latest quarter?

Abionyx Pharma SA's net income for the latest quarter was -2.29.

How did Abionyx Pharma SA's performance compare year-over-year in the latest quarter?

The company's revenue moved from 2.34 in the previous quarter to 2.21 in the latest quarter, and net income moved from -2.09 to -2.29 compared to the previous quarter.

What is Abionyx Pharma SA's net profit margin on a TTM basis?

Abionyx Pharma SA's trailing twelve months (TTM) net profit margin is -96.26%.

How does Abionyx Pharma SA's debt to equity ratio compare to industry standards?

Abionyx Pharma SA's total debt-to-equity ratio is 36.69%.

What is Abionyx Pharma SA's return on investment on a TTM basis?

Abionyx Pharma SA's trailing twelve months (TTM) return on investment (ROI) is -56.76%.

Did Abionyx Pharma SA gain or lose cash last quarter?

In the latest quarter, Abionyx Pharma SA's net change in cash was -2.07 million.

What were Abionyx Pharma SA's total assets and liabilities in the latest quarter?

As of the latest quarter, Abionyx Pharma SA reported total assets of 13.54 million and total liabilities of 3.71 million.

How has Abionyx Pharma SA's total revenue grown this year?

Abionyx Pharma SA's total revenue was 2.34 in the previous quarter and 2.21 in the latest quarter.

What is Abionyx Pharma SA's gross margin on a TTM basis?

Abionyx Pharma SA's trailing twelve months (TTM) gross margin is 18.55%.

What was Abionyx Pharma SA's revenue per share for the latest quarter?

Abionyx Pharma SA's revenue per share for the latest quarter was 0.90.

NSE 30

5,124.53

+3.50

+0.07%

NSE All Share

140,560.33

+227.89

+0.16%

US 30

44,911.00

+125.5

+0.28%

US 500

6,383.60

+13.4

+0.21%

FTSE 100

9,312.30

+3.10

+0.03%

DAX

24,291.48

+0.16

0.00%

South Africa Top 40

94,517.96

+397.56

+0.42%

Market Movers

Name	Last	Chg. %	Vol.
Transcorp Power	258.00	-9.95%	29.47M
Fidelitybk	20.850	+0.48%	16.88M
STANBIC IBTC Bank	94.40	-0.11%	13.00M
UBA	47.95	-0.10%	11.52M
Guaranty Trust Holding	92.95	+0.22%	6.42M
Aradel Holdings	503.00	-3.08%	452.58K
Geregu Power	1,027.40	-10.00%	439.10K

Name	Last	Chg. %	Vol.
FTN Cocoa Processors PLC	6.60	+10.00%	1.46M
Veritas Kapital	1.98	+10.00%	16.40M
Skye Shelter Fund	301.55	+9.99%	936.00
Prestige	1.77	+9.94%	17.35M
Universal Insurance PLC	1.22	+9.91%	17.44M
Austin Laz	2.90	+9.85%	909.04K
Lasaco Assurance PLC	3.46	+9.84%	9.74M

Name	Last	Chg. %	Vol.
BUA Foods	525.00	-10.71%	153.17K
Tripple Gee and Co	5.04	-10.00%	42.40K
John Holt PLC	6.30	-10.00%	129.20K
Infinity Trust Mortgage Bank	6.30	-10.00%	12.36K
Chellarams	9.45	-10.00%	9.86K
Geregu Power	1,027.40	-10.00%	439.10K
Industrial Medical Gases Nigeria	33.35	-9.86%	81.67K

Trending Stocks

Name	Last	Chg. %	Vol.
Jaiz Bank	4.76	+8.43%	7.55M
Ellah Lakes	16.00	+3.90%	2.69M
Champion Brew	18.00	+0.56%	2.88M
Oando Plc	48.55	-0.21%	742.32K
Guaranty Trust Holding	92.95	+0.22%	6.42M

Most Undervalued Stocks

Name	Last	Upside	Fair Value
Aaaaaaa A	5,300.20	+52.49%	8,082.28
A Aaa Aa	515.90	+42.69%	736.14
Aaaaa Aaaaaaa	1,869.10	+37.98%	2,578.98
Aaaaaaaa	64.40	+30.14%	83.81
Aa Aaaaaa	145.50	+26.08%	183.45
Aaaaa Aaaaaa Aaaa	600.00	+16.59%	699.54

Name	Last	Upside	Fair Value
Aaaaaaa A	5,300.20	+52.49%	8,082.28
A Aaa Aa	515.90	+42.69%	736.14
Aaaaa Aaaaaaa	1,869.10	+37.98%	2,578.98
Aaaaaaaa	64.40	+30.14%	83.81
Aa Aaaaaa	145.50	+26.08%	183.45
Aaaaa Aaaaaa Aaaa	600.00	+16.59%	699.54

See full list

Install Our AppScan QR code to install app

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers

Popular Searches

Please try another search

Abionyx Pharma SA (ABNX)

ABNX Financial Summary

Key Ratios

Statements Highlights

Analyst Ratings

Analysts 12-Month Price Target:

Earnings

FAQ

What was Abionyx Pharma SA's net income for the latest quarter?

How did Abionyx Pharma SA's performance compare year-over-year in the latest quarter?

What is Abionyx Pharma SA's net profit margin on a TTM basis?

How does Abionyx Pharma SA's debt to equity ratio compare to industry standards?

What is Abionyx Pharma SA's return on investment on a TTM basis?

Did Abionyx Pharma SA gain or lose cash last quarter?

What were Abionyx Pharma SA's total assets and liabilities in the latest quarter?

How has Abionyx Pharma SA's total revenue grown this year?

What is Abionyx Pharma SA's gross margin on a TTM basis?

What was Abionyx Pharma SA's revenue per share for the latest quarter?

Trending Stocks